Ethionamide is an oral antibacterial medication used primarily in the treatment of multidrug-resistant tuberculosis. It belongs to a class of drugs known as antimycobacterials and is prescribed when standard regimens are ineffective due to bacterial resistance. The drug works by interfering with the synthesis of the bacterial cell wall, leading to growth inhibition of mycobacterium tuberculosis. Its active ingredient is converted inside the bacterium into a reactive metabolite that disrupts mycolic acid formation, a key component of the mycobacterial lipid-rich cell wall. By blocking cell wall assembly the medication causes bacterial death and helps reduce the infective burden in the lungs. The physiological effect of this mechanism is a decrease in the replication of tuberculosis bacilli, allowing the immune system to clear the infection more effectively. Overall the drug provides a targeted therapeutic option for patients with resistant forms of tuberculosis when other agents fail.

Ethionamide is an antibacterial drug used primarily to treat multidrug-resistant tuberculosis infections. It belongs to the class of anti-tubercular agents and works by disrupting the synthesis of mycolic acids in mycobacterial cell walls. The medication is structurally similar to isoniazid and is activated by bacterial enzyme mycobacterial monooxygenase. Once activated it forms reactive metabolites that inhibit the enzyme arabinosyltransferase thereby preventing the formation of essential cell wall components. This inhibition leads to cell death of mycobacterium tuberculosis and enhances the activity of other antitubercular drugs. Clinically it is employed as part of combination therapy when standard regimens are ineffective due to drug resistance. The therapeutic effect arises from interference with lipid metabolism that is vital for bacterial survival.

The most common side effects observed in clinical reports are headache, fatigue, and mild nausea. Some individuals also experience temporary dizziness that usually resolves without intervention. Occasional skin irritation may appear at the site of application but rarely requires treatment. Mild muscle aches have been noted in a small proportion of users. General feelings of restlessness can occur, especially during the first few days of use. These effects are typically short lived and affect only a minority of participants.

The most common side effects often include mild gastrointestinal discomfort. Headaches and occasional dizziness are also frequently reported. Fatigue may appear, especially during the initial adjustment period. Some people experience mild skin irritation or rash. Nausea tends to occur sporadically but usually resolves quickly. Sleep disturbances such as difficulty falling asleep can happen. Most of these effects are temporary and diminish with continued use.